摘要
目的:探讨非布司他联合氢氯噻嗪治疗慢性肾脏病的疗效及对血清胱抑素C(Cys-C)、N末端脑钠肽前体(NT-proBNP)的影响。方法:选择2017年6月至2019年6月我院收治的慢性肾脏病患者80例进行研究,以简单随机分组法分为观察组(n=41)和对照组(n=39)。对照组给予氢氯噻嗪治疗,观察组在对照组的基础上采用非布司他治疗。比较两组患者的临床疗效、血清Cys-C、NT-proBNP、尿素氮(BUN)、血肌酐(SCr)、尿白蛋白(Upro)水平变化情况及不良反应发生情况。结果:观察组总有效率为85.37%,显著高于对照组的64.10%,差异显著(P<0.05);治疗前,两组Cys-C、NT-proBNP水平无显著差异(P>0.05);治疗后,两组Cys-C、NT-proBNP水平均显著下降,且观察组低于对照组(P<0.05);治疗前,两组肾功能水平无显著差异(P>0.05);治疗后,两组BUN、SCr、Upro水平均显著改善,且观察组BUN、SCr、Upro水平低于对照组(P<0.05);观察组不良反应总发生率为14.63%,对照组为20.51%,无显著差异(P>0.05)。结论:在慢性肾脏病患者中应用非布司他联合氢氯噻嗪效果显著,可有效改善患者血清Cys-C、NT-proBNP及肾功能,且不会增加不良反应。
Objective:To investigate the therapeutic effect of non bustatin combined with hydrochlorothiazide on chronic kidney disease and its effect on serum cystatin C(Cys-C)and N-terminal pro brain natriuretic peptide(NT proBNP).Methods:80 patients with chronic kidney disease admitted to our hospital from June 2017 to June 2019 were selected for the study,they were divided into observation group(n=41)and control group(n=39)by simple random grouping.The control group was treated with hydrochlorothiazide and the observation group was treated with febuxostat on the basis of the control group.The clinical efficacy,serum cys-c,nt-probnp,urea nitrogen(BUN),serum creatinine(SCr),urinary albumin(Upro)levels and adverse reactions were compared between the two groups.Results:The total effective rate in the observation group was 85.37%,significantly higher than 64.10%in the control group(P<0.05).Before treatment,there was no significant difference in the levels of cys-c and nt-probnp between the two groups(P>0.05).After treatment,the levels of cys-c and nt-probnp in both groups decreased significantly,and the observation group was lower than the control group(P<0.05).Before treatment,there was no significant difference in renal function between the two groups(P>0.05).After treatment,the levels of BUN,SCr and Upro in both groups were significantly improved,and the levels of BUN,SCr and Upro in the observation group were lower than those in the control group(P<0.05).The total incidence of adverse reactions was 14.63%in the observation group and 20.51%in the control group,with no significant difference(P>0.05).Conclusion:Febuxostat combined with hydrochlorothiazide has a significant effect in patients with chronic kidney disease,which can effectively improve the serum cys-c,nt-probnp and renal function of patients without increasing adverse reactions.
作者
张素明
叶丽萍
程卫
朱云
ZHANG Suming;YE Liping;CHENG Wei(The First People's Hospital of Chuzhou,Anhui Chuzhou 239000,China)
出处
《河北医学》
CAS
2020年第5期763-766,共4页
Hebei Medicine
基金
安徽省自然科学基金项目,(编号:20130812)。
关键词
慢性肾脏病
非布司他
氢氯噻嗪
胱抑素C
N末端脑钠肽前体
Chronic kidney disease
Not buxta
Hydrochlorothiazide
Cystatin C
N-terminal brain natriuretic peptide precursor
